Search results
Cancer cell–immune cell interactions can predict immunotherapy response
Medical Xpress· 55 minutes agoDr. Chan explained that over the past several decades, researchers have had a growing understanding...
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers
MedPage Today· 6 days agocell therapy and haploidentical hematopoietic stem-cell transplantation (HSCT), without...
Increasing T-Cell Survival To Improve Cancer Immunotherapy
Technology Networks· 7 days agoImmunotherapy uses a patient’s own cancer-fighting cells, or T-cells, and adapts them so that they...
A New Weapon Against Cancer: Checkpoint Inhibitors, A Double-Edged Sword
Forbes· 13 hours agoThis article joins a growing series on mono cancer treatments, including novel immunotherapies such...
Bristol Myers Squibb enlists Cellares amid industry manufacturing “land grab”
BioPharma-Reporter· 4 hours agoAs part of the deal, Cellares will optimize BMS’ therapies for production via its automated cell ...
Review highlights the potential and promise of CAR-T cell therapy in autoimmune diseases
Medical Xpress· 7 days agoCurrent therapeutic strategies against AID involve the use of immunosuppressants, glucocorticoids,...
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic...
Digital Journal· 7 hours ago(OTCQB:OTLC) ("Oncotelic"), under which Mosaic intends to acquire rights to certain of Oncotelic's clinical stage necroptosis cancer therapies associated with Oncotelic's ...
Doctors discover tumour in new mum’s chest after ‘pregnancy disguised symptoms’
Yahoo Life UK· 7 hours ago"I am either going to have stem cell transplant with my own cells or CAR T-cell therapy," she...
Biomarkers identified for successful treatment of bone marrow tumors
Medical Xpress· 3 days agoCAR T cell therapy has proven effective in treating various hematological cancers. In a clinical study, researchers ...
...Preclinical Data for Bispecific Claudin 18.2/TGF-β CAR T Program at the American Society of Gene...
ThePress.net· 7 days ago...ImmPACT Bio's bispecific Claudin 18.2 (CLDN18.2)/TGF-β chimeric antigen receptor (CAR) T program for the treatment of solid tumors that express CLDN18.2, including gastric and gastroesophageal junction cancer, as part of a poster presentation at the upcoming American Society of Gene & Cell ...